Abstract
Given the emerging role of microRNA in tumor disease progression, we investigated the association between miRNA 10b expression, liver metastasis, and clinicopathological of colorectal cancer (CRC). Two hundred and forty‐six pairs of samples (including CRC samples and normal adjacent tissues) from CRC patients were collected from May 2004 to May 2009. All samples verified to contain at least 80% tumor cells, and were immediately frozen in liquid nitrogen and stored at −80°C or fixed in 10% formalin for paraffin embedding. The expression of miRNA‐10b in CRC tissues was evaluated using a quantitative real‐time polymerase chain reaction RT‐PCR. Correlation between miR‐10b expression and poor clinicopathological of CRC patients were analyzed using Student's t‐tests and Chi‐square tests. A Kaplan–Meier survival curve was generated following a log‐rank test. miR‐10b expression was up‐regulated in CRC tissues (P < 0.0001) and in patients diagnosed as colorectal liver metastasis (CLM) at initial involvement or during follow‐up. When the Tumor Node Metastasis (TNM) stage was taken into consideration, the expression levels of miR‐10b were positively correlated with advanced TNM stages. In addition, the miR‐10b expression of patients diagnosed as CLM at initial involvement was significantly higher than those without liver metastasis (nCLM). Similarly, those patients developed with CLM during follow‐up (FCLM) was also markedly higher than those with nCLM. miR‐10b expression was also found correlated with advanced stage (P < 0.0001), lymph node metastasis (P = 0.025), venous infiltration (P = 0.007), poorer differentiation (P = 0.002), and served as an independent prognostic factor of poor overall survival (P < 0.0001). This study demonstrated the expression of miR‐10b had strong potential to serve as a noninvasive biomarker for CRC prognosis and predicting liver metastasis.
Highlights
Colorectal cancer (CRC) is a major cause of cancer death worldwide, with over 1.2 million new cases diagnosed each year along with over 600,000 deaths per year [1]
The miR-10b expression of patients diagnosed as colorectal liver metastasis (CLM) at initial involvement (ICLM) was significantly higher than those without liver metastasis (Figure 1C)
This study investigates the potential clinical utility of miR- 10b to serve as noninvasive prognostic and liver metastasis- predictive biomarkers in patients with CRC
Summary
Colorectal cancer (CRC) is a major cause of cancer death worldwide, with over 1.2 million new cases diagnosed each year along with over 600,000 deaths per year [1]. The treatment of CRC definitely improved during the past decades, the 5-y ear survival rate for patients with metastatic CRC remains poor. Liver metastasis, which is the most common site for metastatic spread of CRC, is observed in 20–25% of patients at initial diagnosis, and eventually develops after resection of the primary CRC in a further 40–50% of patients [3]. Radical liver resection remains the only potentially curative therapy for mir-10b and Liver Metastasis of Colorectal Cancer patients with CLM, with reported 5-and 10-year actuarial survival rates of 17–35% and 16–23%, respectively [4]. The prognosis of patients with CLM has been improved by recent advances in multidisciplinary treatments, liver metastasis is still one of the major determinants of survival [6]. It is urgently necessary to unravel the underlying molecular mechanisms and genetic alterations that lead to CRC metastases
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
